Completed PHASE3 INTERVENTIONAL 1-arm NCT01229436

Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex) (POINT X)

Prospective Open-Label Investigation Of The Non-surgical Treatment With Collagenase Clostridium Histolyticum (Xiapex)

Sponsor: Pfizer

Interventions Xiapex

Updated 7 times since 2017 Last updated: Jan 29, 2014 Started: Dec 31, 2010 Primary completion: Oct 31, 2012 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Dupuytren's Contracture and is currently completed. Pfizer leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Neustadt an der Saale, Germany , Barcelona, Spain , Berlin, Germany , Bonn, Germany , Copenhagen, Denmark , Derby, United Kingdom , Elche, Spain , Glasgow, United Kingdom , L'Hospitalet de Llobregat, Spain , Malmo, Sweden and 16 more locations